• Home
  • NEW DAY MEDICINE
  • 9 (95) 2026
  • 3 -9 (95) 2026 - Sulaymanov D.A., Sabirov J.R., Yigitaliev A.B. - ANALYSIS OF HEMATOLOGICAL INDICES OF SYSTEMIC INFLAMMATION IN THYROID CANCER

3 -9 (95) 2026 - Sulaymanov D.A., Sabirov J.R., Yigitaliev A.B. - ANALYSIS OF HEMATOLOGICAL INDICES OF SYSTEMIC INFLAMMATION IN THYROID CANCER

ANALYSIS OF HEMATOLOGICAL INDICES OF SYSTEMIC INFLAMMATION IN THYROID CANCER

Sulaymanov D.A. - Central Asian Medical University, Institute of Immunology and Human Genomics of the Academy of Sciences of the Republic of Uzbekistan

Sabirov J.R. - Institute of Immunology and Human Genomics of the Academy of Sciences of the Republic of Uzbekistan, Tashkent State Medical University

Yigitaliev A.B. - Fergana Medical Institute of Public Health

Resume

In patients with thyroid cancer (TC), a statistically significant increase in all studied hematological indices of systemic inflammation was observed even at the early stages of the disease compared to practically healthy individuals. At the early stages of TC, the SIRI increased by 2.85 times, AISI by 2.79 times, and dNLR by 3.36 times relative to the control group. At advanced stages of the disease, the index values increased even more significantly: SIRI exceeded the norm by 7.12 times, AISI by 6.52 times, and dNLR by 9.31 times. Statistically significant differences were found between the early and advanced stages of the disease: SIRI increased by 2.50 times, AISI by 2.34 times, and dNLR by 2.77 times. The dNLR demonstrated the most pronounced association with tumor progression, which allows considering it as the most sensitive hematological marker of the clinical severity of TC. The obtained results confirm the high diagnostic and prognostic value of SIRI, AISI, and dNLR. Their determination based on a standard complete blood count can be utilized for the early assessment of tumor biological aggressiveness, prediction of clinical severity and metastasis risk, and personalization of treatment strategies in TC patients.

Keywords: thyroid cancer, complete blood count, hematological indices, systemic inflammation, oncological process prediction.

First page

25

Last page

31

For citation:Sulaymanov D.A., Sabirov J.R., Yigitaliev A.B. - ANALYSIS OF HEMATOLOGICAL INDICES OF SYSTEMIC INFLAMMATION IN THYROID CANCER//New Day in Medicine 9(95)2026 25-31 https://newdayworldmedicine.com/en/new_day_medicine/9-95-2026

LIST OF REFERENCES

  1. Chen JH, Zhai ET, Yuan YJ, Wu KM, Xu JB, Peng JJ, Chen CQ, He YL, Cai SR. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23(34):6261-6272. doi:10.3748/wjg.v23.i34.6261.
  2. Cho JG, Byeon HK, Oh KH, Baek SK, Kwon SY, Jung KY, Woo JS. Clinicopathological significance of cancer-associated fibroblasts in papillary thyroid carcinoma: a predictive marker of cervical lymph node metastasis. Eur Arch Otorhinolaryngol. 2018;275(9):2355-2361. doi:10.1007/s00405-018-5061-x.
  3. Jaillon S, Galdiero MR, Del Prete D, Cassatella MA, Garlanda C, Mantovani A. Neutrophils in innate and adaptive immunity. Semin Immunopathol. 2013;35(4):377-394. doi:10.1007/s00281-013-0374-8.
  4. Janas ML, Groves P, Kienzle N, Kelso A. IL-2 regulates perforin and granzyme gene expression in CD8+ T cells independently of its effects on survival and proliferation. J Immunol. 2005;175(12):8003-8010. doi:10.4049/jimmunol.175.12.8003.
  5. Jang JE, Hajdu CH, Liot C, Miller G, Dustin ML, Bar-Sagi D. Crosstalk between regulatory T cells and tumor-associated dendritic cells negates anti-tumor immunity in pancreatic cancer. Cell Rep. 2017;20(3):558-571. doi:10.1016/j.celrep.2017.06.062.
  6. Feng JF, Chen S. Systemic inflammation response index (SIRI) independently predicts survival in patients with esophageal squamous cell carcinoma. Medicine (Baltimore). 2016;95(37).
  7. Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, Zhang X, Wang WM, Qiu SJ, Zhou J, Fan J. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212-6222. doi:10.1158/1078-0432.CCR-14-0442.
  8. Liotti F, Prevete N, Vecchio G, Melillo RM. Recent advances in understanding immune phenotypes of thyroid carcinomas: prognostication and emerging therapies. F1000Res. 2019;8:227. doi:10.12688/f1000research.16677.1.
  9. Liu CL, Lee JJ, Liu TP, Chang YC, Hsu YC, Cheng SP. Blood neutrophil-to-lymphocyte ratio correlates with tumor size in patients with differentiated thyroid cancer. J Surg Oncol. 2013;107(5):493-497. doi:10.1002/jso.23270.
  10. Nickel B, Tan T, Cvejic E, Baade P, McLeod DSA, Pandeya N, Youl P, McCaffery K, Jordan S. Health-related quality of life after diagnosis and treatment of differentiated thyroid cancer and association with type of surgical treatment. JAMA Otolaryngol Head Neck Surg. 2019;145(3):231-238. doi:10.1001/jamaoto.2018.3870.

    file

    download